{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T11:40:51Z","timestamp":1786621251112,"version":"build-2736575974"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015406","name":"Tianjin Municipal Science and Technology Bureau","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015406","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nuclear Medicine and Biology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.nucmedbio.2026.109662","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T14:59:24Z","timestamp":1784645964000},"page":"109662","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Carbonic anhydrase IX-targeted small molecule radiopharmaceuticals: A review of their role in clear cell renal cell carcinoma theranostics"],"prefix":"10.1016","volume":"158-159","author":[{"given":"Yuying","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyue","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8705-5455","authenticated-orcid":false,"given":"Xiangjun","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nucmedbio.2026.109662_bb0005","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.eururo.2022.03.006","article-title":"European Association of Urology Guidelines on Renal Cell Carcinoma: the 2022 update","volume":"82","author":"Ljungberg","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.nucmedbio.2026.109662_bb0010","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.nucmedbio.2026.109662_bb0015","doi-asserted-by":"crossref","first-page":"462","DOI":"10.3109\/21681805.2013.777364","article-title":"Incidentally detected renal cell carcinomas are highly associated with comorbidity and mortality unrelated to renal cell carcinoma","volume":"47","author":"Sand","year":"2013","journal-title":"Scand J Urol"},{"key":"10.1016\/j.nucmedbio.2026.109662_bb0020","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.eururo.2025.02.020","article-title":"European Association of Urology Guidelines on Renal Cell Carcinoma: the 2025 update","volume":"87","author":"Bex","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.nucmedbio.2026.109662_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2025.155919","article-title":"RCC-Ma loss predicts poor survival and metastatic risk in clear cell renal cell carcinoma","volume":"269","author":"Stenzel","year":"2025","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.nucmedbio.2026.109662_bb0030","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/s41581-020-00359-2","article-title":"Clear cell renal cell carcinoma ontogeny and mechanisms of lethality","volume":"17","author":"Jonasch","year":"2021","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.nucmedbio.2026.109662_bb0035","first-page":"2877","article-title":"Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment","volume":"10","author":"Pastorek","year":"1994","journal-title":"Oncogene"},{"key":"10.1016\/j.nucmedbio.2026.109662_bb0040","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.anndiagpath.2018.11.004","article-title":"Papillary pattern in clear cell renal cell carcinoma: Clinicopathologic, morphologic, immunohistochemical and molecular genetic analysis of 23 cases","volume":"38","author":"Alaghehbandan","year":"2019","journal-title":"Ann Diagn Pathol"},{"key":"10.1016\/j.nucmedbio.2026.109662_bb0045","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/ng.2891","article-title":"Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing","volume":"46","author":"Gerlinger","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.nucmedbio.2026.109662_bb0050","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/CCO.0000000000001138","article-title":"Biomarkers in advanced renal cell carcinoma: current practice and future directions","volume":"37","author":"Wong","year":"2025","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.nucmedbio.2026.109662_bb0055","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/cdd.2008.21","article-title":"The role of hypoxia-inducible factors in tumorigenesis","volume":"15","author":"Rankin","year":"2008","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.nucmedbio.2026.109662_bb0060","doi-asserted-by":"crossref","first-page":"5263","DOI":"10.1021\/acs.jproteome.5b00692","article-title":"Combined analyses of the VHL and hypoxia signaling axes in an isogenic pairing of renal clear cell carcinoma cells","volume":"14","author":"Malec","year":"2015","journal-title":"J Proteome Res"},{"key":"10.1016\/j.nucmedbio.2026.109662_bb0065","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/nrd2467","article-title":"Carbonic anhydrases: novel therapeutic applications for inhibitors and activators","volume":"7","author":"Supuran","year":"2008","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.nucmedbio.2026.109662_bb0070","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ejmech.2013.10.027","article-title":"Development and biological evaluation of (9)(9)mTc-sulfonamide derivatives for in vivo visualization of CA IX as surrogate tumor hypoxia markers","volume":"71","author":"Akurathi","year":"2014","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.nucmedbio.2026.109662_bb0075","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.diii.2024.07.003","article-title":"Molecular imaging for non-invasive risk stratification of renal masses","volume":"105","author":"Rowe","year":"2024","journal-title":"Diagn Interv Imag"},{"key":"10.1016\/j.nucmedbio.2026.109662_bb0080","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.semcancer.2022.01.001","article-title":"Carbonic anhydrase IX: a tumor acidification switch in heterogeneity and chemokine regulation","volume":"86","author":"Queen","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.nucmedbio.2026.109662_bb0085","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21197146","article-title":"Carbonic anhydrase IX in renal cell carcinoma, implications for disease management","volume":"21","author":"Courcier","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.nucmedbio.2026.109662_bb0090","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1007\/s00259-021-05271-w","article-title":"Phase I study to assess safety, biodistribution and radiation dosimetry for (89)Zr-girentuximab in patients with renal cell carcinoma","volume":"48","author":"Merkx","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10.1016\/ S1470-2045(24)00402-9","key":"10.1016\/j.nucmedbio.2026.109662_bb0095","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/S1470-2045(24)00402-9","article-title":"[(89)Zr]Zr-girentuximab for PET-CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trial","volume":"25","author":"Shuch","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.nucmedbio.2026.109662_bb0100","article-title":"Comprehensive immunoprofiles of renal cell carcinoma subtypes","volume":"12","author":"Kim","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.nucmedbio.2026.109662_bb0105","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.tips.2025.07.002","article-title":"Human carbonic anhydrase modulators: the past, present, and future","volume":"46","author":"Giovannuzzi","year":"2025","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.nucmedbio.2026.109662_bb0110","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18102179","article-title":"Understanding the contribution of zinc transporters in the function of the early secretory pathway","volume":"18","author":"Kambe","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.nucmedbio.2026.109662_bb0115","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1002\/1878-0261.12931","article-title":"Development and initial clinical testing of a multiplexed circulating tumor cell assay in patients with clear cell renal cell carcinoma","volume":"15","author":"Bade","year":"2021","journal-title":"Mol Oncol"},{"key":"10.1016\/j.nucmedbio.2026.109662_bb0120","doi-asserted-by":"crossref","first-page":"639","DOI":"10.2147\/IJN.S500614","article-title":"Carbonic anhydrase IX targeted polyaspartamide fluorescent probes for tumor imaging","volume":"20","author":"Zhang","year":"2025","journal-title":"Int J Nanomedicine"},{"key":"10.1016\/j.nucmedbio.2026.109662_bb0125","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1021\/acs.molpharmaceut.3c00045","article-title":"Quantitative imaging of hypoxic CAIX-positive tumor areas with low immune cell infiltration in syngeneic mouse tumor models","volume":"20","author":"Boreel","year":"2023","journal-title":"Mol Pharm"},{"key":"10.1016\/j.nucmedbio.2026.109662_bb0130","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1080\/13543784.2018.1548608","article-title":"Carbonic anhydrase inhibitors as emerging agents for the treatment and imaging of hypoxic tumors","volume":"27","author":"Supuran","year":"2018","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.nucmedbio.2026.109662_bb0135","first-page":"116","article-title":"Carbonic anhydrase IX-based tumor imaging and therapy: a review","volume":"39","author":"Lin","year":"2023","journal-title":"Sheng Wu Gong Cheng Xue Bao"},{"key":"10.1016\/j.nucmedbio.2026.109662_bb0140","article-title":"New developments in carbonic anhydrase IX-targeted fluorescence and nuclear imaging agents","volume":"23","author":"Chen","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.nucmedbio.2026.109662_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinorgbio.2024.112547","article-title":"Inhibitor binding to metal-substituted metalloenzyme: sulfonamide affinity for carbonic anhydrase IX","volume":"256","author":"Baronas","year":"2024","journal-title":"J Inorg Biochem"},{"key":"10.1016\/j.nucmedbio.2026.109662_bb0150","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1016\/j.bmc.2017.03.027","article-title":"Synthesis and carbonic anhydrase inhibition of a series of SLC-0111 analogs","volume":"25","author":"Carta","year":"2017","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.nucmedbio.2026.109662_bb0155","doi-asserted-by":"crossref","first-page":"3364","DOI":"10.1158\/0008-5472.CAN-10-4261","article-title":"Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors","volume":"71","author":"Lou","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.nucmedbio.2026.109662_bb0160","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3109\/14756366.2013.773994","article-title":"Synthesis and evaluation of 18F-labeled carbonic anhydrase IX inhibitors for imaging with positron emission tomography","volume":"29","author":"Pan","year":"2014","journal-title":"J Enzyme Inhib Med Chem"},{"key":"10.1016\/j.nucmedbio.2026.109662_bb0165","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1097\/COC.0000000000000691","article-title":"A phase 1 study of SLC-0111, a novel inhibitor of carbonic anhydrase IX, in patients with advanced solid tumors","volume":"43","author":"McDonald","year":"2020","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.nucmedbio.2026.109662_bb0170","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1021\/jm3015348","article-title":"Synthesis and SAR of novel Re\/99mTc-labeled benzenesulfonamide carbonic anhydrase IX inhibitors for molecular imaging of tumor hypoxia","volume":"56","author":"Lu","year":"2013","journal-title":"J Med Chem"},{"key":"10.1016\/j.nucmedbio.2026.109662_bb0175","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1016\/j.bmcl.2014.05.021","article-title":"Synthesis and evaluation of (18)F-labeled tertiary benzenesulfonamides for imaging carbonic anhydrase IX expression in tumours with positron emission tomography","volume":"24","author":"Lau","year":"2014","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.nucmedbio.2026.109662_bb0180","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.7150\/thno.20982","article-title":"Cancer radiotheranostics targeting carbonic anhydrase-IX with (111)In- and (90)Y-labeled ureidosulfonamide scaffold for SPECT imaging and radionuclide-based therapy","volume":"8","author":"Iikuni","year":"2018","journal-title":"Theranostics"},{"key":"10.1016\/j.nucmedbio.2026.109662_bb0185","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1021\/acs.molpharmaceut.8b01120","article-title":"Development of the 99mTc-Hydroxamamide complex as a probe targeting carbonic anhydrase IX","volume":"16","author":"Iikuni","year":"2019","journal-title":"Mol Pharm"},{"key":"10.1016\/j.nucmedbio.2026.109662_bb0190","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0243327","article-title":"PET imaging and pharmacological therapy targeting carbonic anhydrase-IX high-expressing tumors using US2 platform based on bivalent ureidosulfonamide","volume":"15","author":"Iikuni","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.nucmedbio.2026.109662_bb0195","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jinorgbio.2018.04.009","article-title":"Evaluation of (99m)Tc-sulfonamide and sulfocoumarin derivatives for imaging carbonic anhydrase IX expression","volume":"185","author":"Nakai","year":"2018","journal-title":"J Inorg Biochem"},{"key":"10.1016\/j.nucmedbio.2026.109662_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117443","article-title":"Synthesis and in vitro evaluation of radioiodine labeled hypoxia-targeted drugs containing 2-nitroimidazole and benzenesulfonamide groups","volume":"289","author":"Liu","year":"2025","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.nucmedbio.2026.109662_bb0205","article-title":"Carbonic anhydrase IX-targeted SMDCs for cancer precision treatment","volume":"37","author":"Zhang","year":"2026","journal-title":"Chin Chem Lett"},{"key":"10.1016\/j.nucmedbio.2026.109662_bb0210","first-page":"1","article-title":"Radiobiological investigations of a [212Pb]Pb-carbonic anhydrase IX-targeting small-molecule ligand in renal cell carcinoma and colorectal cancer models","author":"Kristiansen","year":"2026","journal-title":"Int J Radiat Biol"},{"key":"10.1016\/j.nucmedbio.2026.109662_bb0215","doi-asserted-by":"crossref","first-page":"33733","DOI":"10.18632\/oncotarget.5254","article-title":"Imaging of carbonic anhydrase IX with an 111In-labeled dual-motif inhibitor","volume":"32","author":"Yang","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.nucmedbio.2026.109662_bb0220","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/jlcr.3906","article-title":"Process validation, current good manufacturing practice production, dosimetry, and toxicity studies of the carbonic anhydrase IX imaging agent [(111) in]in-XYIMSR-01 for phase I regulatory approval","volume":"64","author":"De Silva","year":"2021","journal-title":"J Labelled Comp Radiopharm"},{"key":"10.1016\/j.nucmedbio.2026.109662_bb0225","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s11307-025-02004-5","article-title":"Synthesis and construction of I-124 labeled small molecular probe for noninvasive PET imaging of CAIX expression","volume":"27","author":"Yang","year":"2025","journal-title":"Mol Imaging Biol"},{"key":"10.1016\/j.nucmedbio.2026.109662_bb0230","doi-asserted-by":"crossref","first-page":"56471","DOI":"10.18632\/oncotarget.10602","article-title":"[64Cu]XYIMSR-06: a dual-motif CAIX ligand for PET imaging of clear cell renal cell carcinoma","volume":"35","author":"Minn","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.nucmedbio.2026.109662_bb0235","doi-asserted-by":"crossref","first-page":"943","DOI":"10.2967\/jnumed.115.170514","article-title":"A 99mTc-labeled ligand of carbonic anhydrase IX selectively targets renal cell carcinoma in vivo","volume":"57","author":"Krall","year":"2016","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2026.109662_bb0240","doi-asserted-by":"crossref","first-page":"360","DOI":"10.2967\/jnumed.120.245530","article-title":"A microdosing study with 99mTc-PHC-102 for the SPECT\/CT imaging of primary and metastatic lesions in renal cell carcinoma patients","volume":"62","author":"Kulterer","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2026.109662_bb0245","doi-asserted-by":"crossref","first-page":"14726","DOI":"10.1021\/acsomega.8b02350","article-title":"In vivo antitumor activity of a novel acetazolamide-Cryptophycin conjugate for the treatment of renal cell carcinomas","volume":"3","author":"Cazzamalli","year":"2018","journal-title":"ACS Omega"},{"key":"10.1016\/j.nucmedbio.2026.109662_bb0250","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1021\/acs.molpharmaceut.4c00104","article-title":"A CAIX dual-targeting small-molecule probe for noninvasive imaging of ccRCC","volume":"21","author":"He","year":"2024","journal-title":"Mol Pharm"},{"key":"10.1016\/j.nucmedbio.2026.109662_bb0255","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1007\/s00259-023-06248-7","article-title":"Preclinical and pilot clinical evaluation of a small-molecule carbonic anhydrase IX targeting PET tracer in clear cell renal cell carcinoma","volume":"50","author":"Zhu","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2026.109662_bb0260","article-title":"(68)Ga-NY104 PET\/CT in the differential diagnosis of FDG-negative renal masses: a two-case illustration of clear cell carcinoma versus renal hemangioma","volume":"15","author":"Yan","year":"2025","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.nucmedbio.2026.109662_bb0265","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1007\/s00259-024-07007-y","article-title":"Evaluation of the safety, biodistribution, dosimetry of [(18)F]AlF-NYM005 and initial experience in clear cell renal cell carcinoma: an interim analysis of a prospective trial","volume":"52","author":"Yang","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2026.109662_bb0270","first-page":"1884","article-title":"Value of [(68)Ga]Ga-NYM046 PET\/CT, in comparison with (18)F-FDG PET\/CT, for diagnosis of clear cell renal cell carcinoma","volume":"65","author":"Lou","year":"2024","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2026.109662_bb0275","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1021\/acs.bioconjchem.5c00041","article-title":"[(177)Lu]Lu-XYIMSR-01: a novel CAIX-targeted radiotherapeutic for enhanced treatment of malignant glioma","volume":"36","author":"Wang","year":"2025","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.nucmedbio.2026.109662_bb0280","article-title":"Carbonic anhydrase IX-targeted molecular probe for positron emission tomography imaging of clear cell renal cell carcinoma","author":"Qiu","year":"2025","journal-title":"Chem Biomed Imag"},{"key":"10.1016\/j.nucmedbio.2026.109662_bb0285","doi-asserted-by":"crossref","first-page":"761","DOI":"10.2967\/jnumed.123.266309","article-title":"Preclinical characterization of DPI-4452: a (68)Ga\/(177)Lu theranostic ligand for carbonic anhydrase IX","volume":"65","author":"Massiere","year":"2024","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2026.109662_bb0290","doi-asserted-by":"crossref","first-page":"740","DOI":"10.2967\/jnumed.123.267175","article-title":"First-in-human safety, imaging, and dosimetry of a carbonic anhydrase IX-targeting peptide, [(68)Ga]Ga-DPI-4452, in patients with clear cell renal cell carcinoma","volume":"65","author":"Hofman","year":"2024","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2026.109662_bb0295","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2024-6024","article-title":"A novel carbonic anhydrase IX targeting radiopeptide, 64Cu-PD-32766 and 177Lu-PD-32766, exhibit promising theranostic potential in ccRCC tumors","volume":"84","author":"Mizukoshi","year":"2024","journal-title":"Cancer Res"},{"key":"10.1016\/j.nucmedbio.2026.109662_bb0300","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s11307-015-0831-y","article-title":"[(18)F]VM4-037 MicroPET imaging and biodistribution of two in vivo CAIX-expressing tumor models","volume":"17","author":"Peeters","year":"2015","journal-title":"Mol Imaging Biol"},{"key":"10.1016\/j.nucmedbio.2026.109662_bb0305","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s00261-015-0599-1","article-title":"PET\/CT imaging of renal cell carcinoma with (18)F-VM4-037: a phase II pilot study","volume":"41","author":"Turkbey","year":"2016","journal-title":"Abdom Radiol (NY)"},{"key":"10.1016\/j.nucmedbio.2026.109662_bb0310","doi-asserted-by":"crossref","first-page":"5571","DOI":"10.1021\/acsomega.2c06954","article-title":"Novel Thiopyrano[2,3-d]thiazole-pyrazole hybrids as potential nonsulfonamide human carbonic anhydrase IX and XII inhibitors: design, synthesis, and biochemical studies","volume":"8","author":"Metwally","year":"2023","journal-title":"ACS Omega"},{"key":"10.1016\/j.nucmedbio.2026.109662_bb0315","doi-asserted-by":"crossref","first-page":"15892","DOI":"10.1021\/acs.jmedchem.4c01563","article-title":"Harnessing nitric oxide-donating benzofuroxans for targeted inhibition of carbonic anhydrase IX in cancer","volume":"67","author":"Bua","year":"2024","journal-title":"J Med Chem"}],"container-title":["Nuclear Medicine and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805126000612?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805126000612?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T11:26:05Z","timestamp":1786620365000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969805126000612"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":63,"alternative-id":["S0969805126000612"],"URL":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2026.109662","relation":{},"ISSN":["0969-8051"],"issn-type":[{"value":"0969-8051","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Carbonic anhydrase IX-targeted small molecule radiopharmaceuticals: A review of their role in clear cell renal cell carcinoma theranostics","name":"articletitle","label":"Article Title"},{"value":"Nuclear Medicine and Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2026.109662","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109662"}}